Skip to main content

Table 1 Key model parameters for describing the effect of treatment on transmission

From: Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment

Description

Symbol

Value(s)

References

Untreated infections

 Mean duration of state (days)

  

[17]

  D (clinical disease)

dD

5

 

  A (asymptomatic)

dA

195

 

  U (submicroscopic)

dU

84

 

 Probability of human-to-mosquito transmission per mosquito bite from individuals in state

  

[17]

  D (clinical disease)

cD

0.0868596

 

  A (asymptomatic)

cA

cD > cA > cU varies by immunity

 

  U (submicroscopic)

cU

0.0023444

 

 Total infectivity over the infectious period in untreated, initially symptomatic infections

Otot

cDdD + cAdA + cUdU

–

 Proportion of infections which develop symptoms

φ

0.00038–0.81 (immunity-dependent)

 

Treated infections

 Drug efficacy: probability the drug eventually clears parasites

peff

0.97

[6]

 % reduction Otot in total infectivity over the infectious period achieved by treatment with:

  

[17]

  SP

Ored

79.1%

 

  ACT

 

92.7%

 

  ACT + primaquine

 

100%

 

 Mean duration of state

  

[17]

  PDT, PAU, or PS (prophylaxis)

dP

3, 30, 60

 

  T

dT

5

 

 Probability of human-to-mosquito transmission per mosquito bite from individuals in state

  

This paper

  T (will soon receive treatment)

cT

cD

 

  PDT (prophylaxis)

cPDT

Otot * (1 − Ored/100)/dP

 

  PAU (prophylaxis)

cPAU

cA * cPDT/cD

 

 MDA coverage: proportion of individuals receiving MDA

fMDA

0.8

–

 Case management coverage: proportion of cases treated

fT

0.4–1

–

  1. A full parameter list is given in [17]